These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17302732)

  • 1. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.
    Pelli N; Floreani A; Torre F; Delfino A; Baragiotta A; Contini P; Basso M; Picciotto A
    Clin Exp Immunol; 2007 Apr; 148(1):85-9. PubMed ID: 17302732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation.
    Nomura S; Ishii K; Inami N; Uoshima N; Ishida H; Yoshihara T; Kitayama H; Hayashi K
    Transpl Immunol; 2007 Nov; 18(2):115-21. PubMed ID: 18005854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis.
    Liang Y; Yang Z; Li C; Zhu Y; Zhang L; Zhong R
    Clin Exp Med; 2008 Mar; 8(1):1-7. PubMed ID: 18385934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis.
    Moreno M; Sáenz-Cuesta M; Castilló J; Cantó E; Negrotto L; Vidal-Jordana A; Montalban X; Comabella M
    J Neuroimmunol; 2013 Oct; 263(1-2):152-4. PubMed ID: 23932896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis.
    Tsikrikoni A; Kyriakou DS; Rigopoulou EI; Alexandrakis MG; Zachou K; Passam F; Dalekos GN
    J Hepatol; 2005 Mar; 42(3):393-9. PubMed ID: 15710223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoteichoic acid may affect the pathogenesis of bile duct damage in primary biliary cirrhosis.
    Haruta I; Hashimoto E; Kato Y; Kikuchi K; Kato H; Yagi J; Uchiyama T; Kobayash M; Shiratori K
    Autoimmunity; 2006 Mar; 39(2):129-35. PubMed ID: 16698669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
    Ben Bahria-Sediki I; Chebil M; Sampaio C; Martel-Frachet V; Cherif M; Zermani R; Rammeh S; Ben Ammar Gaaied A; Bettaieb A
    Urol Int; 2018; 100(4):476-484. PubMed ID: 29719304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
    Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
    J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.
    Bortolami M; Kotsafti A; Cardin R; Farinati F
    J Viral Hepat; 2008 Jul; 15(7):515-22. PubMed ID: 18331250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
    Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
    Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C.
    Zaki Mel S; Auf FA; Ghawalby NA; Saddal NM
    Immunol Invest; 2008; 37(2):163-70. PubMed ID: 18300041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of TRAIL and its receptors in viral hepatitis.
    Mundt B; Kühnel F; Zender L; Paul Y; Tillmann H; Trautwein C; Manns MP; Kubicka S
    FASEB J; 2003 Jan; 17(1):94-6. PubMed ID: 12475902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake.
    Mundt B; Wirth T; Zender L; Waltemathe M; Trautwein C; Manns MP; Kühnel F; Kubicka S
    Gut; 2005 Nov; 54(11):1590-6. PubMed ID: 16227360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells.
    Afford SC; Ahmed-Choudhury J; Randhawa S; Russell C; Youster J; Crosby HA; Eliopoulos A; Hubscher SG; Young LS; Adams DH
    FASEB J; 2001 Nov; 15(13):2345-54. PubMed ID: 11689460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis.
    Harada K; Ozaki S; Gershwin ME; Nakanuma Y
    Hepatology; 1997 Dec; 26(6):1399-405. PubMed ID: 9397977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.
    Tanaka H; Ito T; Kyo T; Kimura A
    Eur J Haematol; 2007 May; 78(5):389-98. PubMed ID: 17432976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
    Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
    Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.